featured
Optimal Threshold and Prognostic Utility of Pre-Treatment Hemoglobin Level as a Biomarker for Survival in Patients With Head and Neck Cancer Receiving Chemoradiation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Oral Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Defining the optimal threshold and prognostic utility of pre-treatment hemoglobin level as a biomarker for survival outcomes in head and neck cancer patients receiving chemoradiation
Oral Oncol 2022 Oct 01;133(2022)106054, SJ Ma, H Yu, M Khan, B Yu, S Santhosh, U Chatterjee, J Gill, A Iovoli, M Farrugia, K Wooten, V Gupta, R McSpadden, MA Kuriakose, MR Markiewicz, A Al-Afif, WL Hicks, ME Platek, M Seshadri, AD Ray, E Repasky, AK SinghFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.